Windtree Therapeutics, a biotech firm that recently announced a $700 million BNB treasury strategy, has been delisted from Nasdaq for failing to meet a listing requirement. The BNB Inspired Rally and Subsequent Plunge Biotech company Windtree Therapeutics, which announced a massive $700 million BNB treasury move, has had its stock delisted from Nasdaq for failing
